为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
微小 RNA 在肝细胞癌治疗中的作用：规划前行路径
英文原题：MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward.
查看英文原题
MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
MicroRNA（miRNA）参与调节基因表达，在肝细胞癌（HCC）预后评估和治疗中均显示出重要潜力。与其他肿瘤类似，HCC很少孤立发生，而是在同时包含促癌和抑癌因素的微环境中演变。miRNA技术若与合适递送载体结合，可直接作用于这些因素，从而抑制肿瘤形成和进展。该领域持续研究有望在不久的将来为HCC带来更有效的多模式治疗方法。
展开英文摘要原文
MicroRNAs (miRNAs) are recognized for their involvement in the regulation of gene expression and exhibit significant potential in both the prognostic assessment and treatment of hepatocellular carcinoma (HCC). HCC, like other tumors, seldom occurs in isolation; instead, it evolves within a microenvironment featuring oncogenic and tumor-suppressive elements.
When combined with suitable delivery vehicles, miRNA technology provides the capability to directly engage with these elements, thereby hindering tumor formation and progression. Ongoing research in this domain holds the promise of enabling a more efficacious and multi-modal treatment approach for HCC in the near future.
论文信息
- 作者
- Lin HT、Castaneda AFA、Krishna SG、Mumtaz K
- 第一作者单位
- Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.United States
- 通讯作者单位
- Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States. khalid.mumtaz@osumc.edu.United States
- 文献类型
- 社论
- 期刊
- World journal of gastroenterology2024 Mar 21
- 原文标识
- PubMed 38617456 · DOI 10.3748/wjg.v30.i11.1470
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →